Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
So, three MMs conspired for 20mins to hide three mid-sized trades, then one MM stepped in to correct it?
Ok. You’re welcome to believe what you like, but it would take more evidence than that to convince me :)
Wasn’t this asked at the last presentation?
If you go thru the recording, you can get it directly from Tim.
From memory, his response was along the lines of “they stopped returning our calls several months ago”.
I think that tells us all we need to know.
£Bn market cap is £14.70 @ 68M shares. This assumes no dilution / raising by equity issue. We can get there if 737 deal finances 1801 &1802.
GSK acquired Sierra for $1.9 Bn - that’s basically for one Ph3 product which was tested for just *one* indication.
Sareum potentially have two fully owned products for multiple indications plus a percentage of royalties for a third.
If, and I stress if, all goes perfectly, we could be looking at a multiplier of 3x the Sierra valuation. Multiply again for greater gross sale value as Sierra’s momelotenib was in a niche market?
Obviously lots of caveats apply, fair seas and a following wind :) but I don’t think anyone would turn their nose up at an SP of £45
GLA.
You’d sort of assume that as 1801 isn’t dabbling with any genetic engineering, cloning, human embryos, and TYK2/JAK1 is effectively existing technology, there shouldn’t be any red flags to an ethics committee?
Nice post, SOG.
Now this might be a bit random, as I’m not a pharma person, but it seems to me that a comment someone once made to me, that the pharma industry is very incestuous, seems to apply here…. Let me explain:
We’ve got Udai Banerai and Michelle Garrett well plugged into the CRUK/CPF development programmes, but AZ5363 (a preclinical asset) into the mix as well.
https://pubmed.ncbi.nlm.nih.gov/29066505/
Now, Sierra (licensed?) another Astra product, AZD5153 and if I remember correctly, were planning combo trials with AZD5153 and SRA737? I remember (vagueley) the pipeline page on Sierra’s web site but of course that’s lost now that they are part of GSK. I my have to have a play with the way back machine at the weekend to confirm this.
Just strikes me as a bit weird that some new dude arrives on these boards a couple of days ago, mentioning AZ when there’s all this ancient and recent history, like a little love triangle with CRUK, Sierra and Astra linked by the above people. Plus GSK stirring it up by acquiring Sierra whilst Tim (and John?) are ex-GSK guys.
Told you it was going to be random, didn’t I?
:)
Anyone care to add more links or branches to this pharma family tree? For example, nobody has mentioned Tripana Sen for ages. But I’m sure there are other key people as well?
All the best,
SCH.
SOG - it’s really a very simple reason why departments like MHRA aren’t performing - they’ve been stripped of funding and resources.
Here’s a comparison - the Marine Accidents Investigation Branch used to get full reports done in about 6 months. Now they are taking up to three and a half years, even for fatal accidents. They’re firefighting and issuing interim reports to cover the basic legal aspects and support court cases, but the full reports are stuck and I wonder if they will ever be completed.
Have a look at the dates on these…. it’s shocking:
https://www.gov.uk/government/publications/marine-accident-investigation-branch-current-investigations/marine-accident-investigation-branch-current-investigations
RSI=79 !
https://youtu.be/kUsFWO08CO0
There are many articles that agree with you, Seawolf!
This is just one….
https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.3095
:)
2pm update:
Crossed the 90trades that I look for as a sign of decent volume
Trades 93
Vol Sold 115,648
Vol Bought 115,473
But the bought and sold are clearly wrong - there are pairs of 20k trades recorded as sells which are obviously B&ISA transactions, so for every instance of that it’s 40k of sells incorrectly recorded. There’s certainly one, maybe more, of there today.
- who invited Parker to the JP Morgan event? Would be interesting g to know.
Anyway, they bid up from $110 to $200 a share. Raising the deal value to $10.8 Bn.
That’s one massive deal!